Development of a Live Topical Microbicide for Women
女性外用活杀微生物剂的开发
基本信息
- 批准号:8126267
- 负责人:
- 金额:$ 36.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-30 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAnimalsAntibiotic ResistanceAntibioticsBacteriaBacterial VaginosisBiological MarkersBiological ProductsBiomedical EngineeringCell LineCervicalChinese PeopleChromosomesCoculture TechniquesCollectionConsultationsCyanovirin-NDevelopmentDoseDrug EvaluationDrug FormulationsEpidemiologic StudiesEpithelial CellsEpitheliumEvaluation ResearchFemaleGenerationsGeneticGenetically Modified OrganismsGenital systemGenome StabilityHIVHIV Entry InhibitorsHIV-1HeterosexualsHumanHuman VolunteersHydrogenHydrogen PeroxideImmuneIn SituInfectionInvestigational DrugsInvestigational New Drug ApplicationLactobacillusLeadLifeLocal MicrobicidesMacaca mulattaModelingOpportunistic InfectionsOrganismPharmacologic SubstancePhasePhase II Clinical TrialsProteinsRecombinantsRecurrenceRiskSafetySeminal PlasmaSexually Transmitted DiseasesTherapeuticTransferenceUnited States Dept. of Health and Human ServicesUrinary tract infectionVaginaViralWomanWorkbasedesignimmunogenicityimmunotoxicitymanufacturing processmicrobicidenonhuman primatenovelpathogenpre-clinicalpreclinical efficacypreclinical safetypreclinical studypreventself-renewalsimian human immunodeficiency virustransmission processvaginal lactobacillivolunteer
项目摘要
This proposal outlines the development of a novel live microbicide, termed MucoCept,
designed to prevent heterosexual HIV transmission in women. MucoCept is an H2O2-
producing vaginal L. jensenii 1153 strain that has been genetically modified to
constitutively secrete a potent anti-HIV protein, cyanovirin-N (CV-N). We propose to
assess the safety, tolerability and affect on innate genital tract immune factor and
colonization following application of a CV-N expressing L. jensenii designated 1153-
1666 using the Non-Human Primate model. In addition, we will assess and confirm the
clearance of the L. jensenii 1153-1666 strain in the Non-Human primate following
antibiotic administration.
该提案概述了一种新型活杀微生物剂MucoCept的开发,
旨在预防女性通过异性性行为传播艾滋病毒。MucoCept是一种H2 O2-
产生阴道L. Jensenii 1153菌株,该菌株已被遗传修饰,
组成性分泌一种有效的抗HIV蛋白,氰病毒蛋白-N(CV-N)。我们建议
评估安全性、耐受性和对先天生殖道免疫因子的影响,
在施用表达CV-N的L.詹塞尼命名为1153-
1666.第1666章非人类的动物此外,我们会评估及确认
L的间隙。jensenii 1153-1666菌株在非人灵长类动物中的
抗生素管理。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women.
- DOI:10.1371/journal.pone.0122730
- 发表时间:2015
- 期刊:
- 影响因子:3.7
- 作者:Lagenaur LA;Swedek I;Lee PP;Parks TP
- 通讯作者:Parks TP
Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.
- DOI:10.1038/mi.2011.30
- 发表时间:2011-11
- 期刊:
- 影响因子:8
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laurel A. Lagenaur其他文献
Laurel A. Lagenaur的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laurel A. Lagenaur', 18)}}的其他基金
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial
MucoCept-CVN,一种基因增强的阴道乳杆菌菌株,用于预防女性感染艾滋病毒:首次人体临床试验的配方最终确定
- 批准号:
9905651 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial
MucoCept-CVN,一种基因增强的阴道乳杆菌菌株,用于预防女性感染艾滋病毒:首次人体临床试验的配方最终确定
- 批准号:
10223989 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Development of a rapid point of care diagnostic,to monitor MucoCept-CVN, an HIV-targeted biotherapy,
开发快速护理诊断,以监测 MucoCept-CVN(一种针对 HIV 的生物疗法)
- 批准号:
9137087 - 财政年份:2016
- 资助金额:
$ 36.45万 - 项目类别:
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bioengineered to secrete broadly neutralizing domain antibodies
使用经生物工程改造可分泌广泛中和域抗体的共生阴道乳杆菌提供针对 HIV 的被动免疫
- 批准号:
8658658 - 财政年份:2012
- 资助金额:
$ 36.45万 - 项目类别:
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bi
使用共生阴道双乳杆菌提供针对 HIV 的被动免疫
- 批准号:
8329194 - 财政年份:2012
- 资助金额:
$ 36.45万 - 项目类别:
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bioengineered to secrete broadly neutralizing domain antibodies
使用经生物工程改造可分泌广泛中和域抗体的共生阴道乳杆菌提供针对 HIV 的被动免疫
- 批准号:
8906724 - 财政年份:2012
- 资助金额:
$ 36.45万 - 项目类别:
Development of Bacterial Therapeutics Targeting Bacterial Vaginosis-Associated Bi
针对细菌性阴道病相关双歧杆菌的细菌疗法的开发
- 批准号:
7925857 - 财政年份:2010
- 资助金额:
$ 36.45万 - 项目类别:
Development of a Live Topical Microbicide for Women
女性外用活杀微生物剂的开发
- 批准号:
8145510 - 财政年份:2010
- 资助金额:
$ 36.45万 - 项目类别:
Development of a Live Combinational Microbicide for Women
女性用活性复合杀微生物剂的开发
- 批准号:
7786986 - 财政年份:2009
- 资助金额:
$ 36.45万 - 项目类别:
Development of a Live Topical Microbicide for Women
女性外用活杀微生物剂的开发
- 批准号:
7937801 - 财政年份:2007
- 资助金额:
$ 36.45万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Fellowship Programs